Interim results from a multicenter European study suggest serial amino acid PET can detect early metabolic responses to vorasidenib (Voranigo) in IDH-mutant glioma earlier than structural MRI workflows. PET Response Assessment in Neuro-Oncology (RANO) 1.0 identified partial responses in 29% of evaluable patients versus 6% under RANO 2.0 MRI criteria, with median time to response of 4 months versus 8 months.
Get the Daily Brief